Connect your agent to akta.pro and build company lists like this across sectors and geos.
Private digital therapeutics companies, All stages, ranked by total capital raised. Data compiled .
| Company | Category | Most Recent Round | Total Funding | Offering | Management | Revenue Model |
|---|---|---|---|---|---|---|
| Click Therapeutics ๐บ๐ธ New York, NY | Prescription Digital Therapeutics | Series D Apr 2026 | Funding $1.06B | FDA-authorized prescription digital therapeutics for MDD (Rejoyn), episodic migraine (CT-132) and type 2 diabetes (AspyreRx), plus the Click SE Software-Enhanced Drug platform combined with pharma partners. | David Benshoof Klein Founder & CEO Randall Stanicky CFO Han Chiu CTO Shaheen Lakhan Chief Medical and Scientific Officer | Licensing Royalties Subscription Recurring Professional Services |
| Glooko ๐บ๐ธ Palo Alto, CA | Diabetes Digital Therapeutics & Dose Decision Support | Series F Oct 2024 | Funding $301M | Cloud-based diabetes management platform aggregating 200+ device integrations with the FDA-cleared EndoTool inpatient insulin dosing system for a hospital-to-home continuum. | Mike Alvarez CEO Mark Clements Chief Medical and Strategy Officer | Subscription Recurring Freemium |
| Big Health ๐บ๐ธ San Francisco, CA | Prescription Digital Therapeutics | Series C Jan 2022 | Funding $159M | FDA-cleared prescription digital CBT programs (SleepioRx, DaylightRx) plus consumer wellness apps (Sleepio, Daylight) for insomnia, anxiety and depression. | Yael Berman CEO Peter Hames Co-Founder and President Colin Espie Co-Founder | One Time License Subscription Recurring Freemium |
| Sidekick Health Reykjavik | Digital Therapeutics | Series B May 2022 | Funding $126M | Multi-condition digital therapeutics platform covering 20+ chronic conditions, including Germany DiGA-approved prescription digital therapeutics zanadio (obesity) and PINK! Coach (breast cancer). | Tryggvi Thorgeirsson CEO & Co-founder Saemundur Oddsson Chief Medical Officer & Co-founder | Subscription Recurring |
| Mahana Therapeutics ๐บ๐ธ San Francisco, CA | Digital Therapeutics | Series B Aug 2021 | Funding $81.6M | Nerva, an evidence-based gut-directed hypnotherapy digital therapeutic for IBS, reaching over 300,000 consumers and 19,000+ referring clinicians. | Simon Levy Co-founder & CTO Robert Paull Co-founder | Subscription Recurring |
| Glytec ๐บ๐ธ Atlanta, GA | Diabetes Digital Therapeutics & Dose Decision Support | Series A Sep 2011 | Funding $78.0M | GlytecOne cloud-based glycemic management platform anchored by the FDA-cleared Glucommander insulin dosing algorithm, used across 400+ hospitals. | Patrick F. Cua President & CEO Jordan Messler Chief Medical Officer | Subscription Recurring |
| ieso ๐ฌ๐ง Cambridge | Behavioral Health Digital Therapeutics | Series B Nov 2021 | Funding $77.9M | Velora, an AI-powered conversational digital therapeutic delivering CBT-based support for anxiety and depression, licensed via API/white-label to digital health companies and employers. | Nigel Pitchford CEO Andy Blackwell Group Chief Science & Strategy Officer | Subscription Recurring |
| AppliedVR ๐บ๐ธ Van Nuys, CA | Immersive Digital Therapeutics | Series B Nov 2021 | Funding $71.0M | RelieVRx, the first FDA-authorized prescription VR digital therapeutic for chronic lower back pain, plus SustainVR for veterans. | Matthew Stoudt Co-Founder and CEO Josh Sackman Co-Founder and President | Hardware Sales |
| MedRhythms ๐บ๐ธ Boston, MA | Prescription Digital Therapeutics | Series B Nov 2021 | Funding $57.3M | InTandem and MOVIVE, FDA-listed Class II prescription digital therapeutics combining gait sensors and personalized music (rhythmic auditory stimulation) for stroke and Parkinson's rehabilitation. | Lawrence Jasinski CEO Brian Harris Co-Founder and Chief Scientific Officer | Subscription Recurring |
| Welldoc ๐บ๐ธ Columbia, MD | Cardiometabolic Digital Therapeutics | Series B Mar 2016 | Funding $55.2M | BlueStar, an FDA-cleared AI-powered cardiometabolic digital therapeutics platform for diabetes, hypertension, weight and CKD, reaching 53 million covered lives. | Kevin McRaith President and CEO Anand Iyer Chief AI Officer | Subscription Recurring |
| S-Alpha Therapeutics ๐ฐ๐ท Seoul | Pediatric Digital Therapeutics | Series C Nov 2025 | Funding $54.0M | SAT-001 (MyoHabit), a digital therapeutic device for pediatric myopia progression, plus a six-asset DTx pipeline spanning cognitive, oncology and stress indications. | Choi Heon CEO Myung Joon Kim Chief Medical Officer & Co-founder | One Time License Licensing Royalties |
| Freespira ๐บ๐ธ Kirkland, WA | Prescription Digital Therapeutics | Series E Apr 2024 | Funding $44.3M | FDA-cleared at-home digital therapeutic using capnometry-guided breathing retraining over a 28-day protocol to treat panic disorder and PTSD. | Joseph Perekupka CEO Robert Cuyler Chief Clinical Officer | Subscription Recurring One Time License Usage Based |
| HelloBetter ๐ฉ๐ช Berlin | Prescription Digital Therapeutics | Series A Sep 2023 | Funding $37.4M | Ten digital mental health therapy programs, six BfArM-approved and DiGA-reimbursed, for anxiety, depression and insomnia, serving 120,000+ patients in Germany. | Hannes Klรถpper CEO & Co-Founder David Daniel Ebert Founder, Managing Director & CSO | Subscription Recurring |
| Sweetch ๐ฎ๐ฑ Tel Aviv-Yafo | Digital Therapeutics | Series A Apr 2024 | Funding $35.5M | JITAI (Just-in-Time Adaptive Intervention) digital therapeutics platform combining behavioral science and AI to deliver hyper-personalized chronic-condition interventions for pharma, payer and provider partners. | Dana Chanan CEO and Founder Jennifer Meller Chief Medical Officer | Subscription Recurring |
| Swing Therapeutics ๐บ๐ธ San Francisco, CA | Prescription Digital Therapeutics | Series A | Funding $34.0M | Stanza, an FDA-cleared prescription digital therapeutic delivering Acceptance and Commitment Therapy via smartphone for adults with fibromyalgia. | Mike Rosenbluth CEO and Founder Andrea Chadwick Medical Director | Subscription Recurring |
| BestCovered ๐จ๐ณ Shanghai | Cognitive Digital Therapeutics | Series A Nov 2022 | Funding $31.4M | Voice-biomarker cognitive screening and multi-dimensional cognitive rehabilitation training software, dual NMPA (China) and FDA Class II certified for cognitive impairment. | Qiu Yan Vice President Chen Nan Chief Technology Officer | Subscription Recurring Licensing Royalties |
| Constant Therapy Health ๐บ๐ธ Boston, MA | AI Digital Therapeutics | Series A | Funding $30.0M | AI-personalized speech, language and cognitive therapy digital therapeutic for stroke, TBI and aphasia patients, built on the proprietary NeuroPerformance Engine with FDA Breakthrough Device designation. | Veera Anantha Founder and CEO Swathi Kiran Founding Scientist and Co-Founder | Subscription Recurring Licensing Royalties |
| Mightier ๐บ๐ธ Boston, MA | Pediatric Digital Therapeutics | Series B Dec 2021 | Funding $29.2M | Biofeedback gaming digital therapeutic (heart sensor + game app) clinically validated at Harvard and Boston Children's Hospital to help children ages 6-14 regulate emotions. | Craig Lund Co-founder & CEO Jason Kahn Co-founder & Chief Science Officer | Subscription Recurring One Time License |
| nyra health ๐ฆ๐น Vienna | Digital Neurorehabilitation | Series A Feb 2026 | Funding $28.5M | CE-certified AI-powered digital neurotherapy app (myReha) delivering speech, cognitive and motor rehabilitation for stroke, dementia and Parkinson's patients, reimbursed by 28 German insurers. | Moritz Schรถllauf Co-Founder and CEO Mario Zusag Co-Founder and CTO | Subscription Recurring |
| Emocog ๐ฐ๐ท Seoul | Cognitive Digital Therapeutics | Series B Dec 2024 | Funding $27.2M | Cogthera, an MFDS-approved (South Korea) smartphone-based cognitive training digital therapeutic for mild cognitive impairment, pursuing Germany's DiGA fast-track pathway. | Yoo Hun Noh Co-CEO & Founder Jun Young Lee Co-CEO & Founder | Subscription Recurring |
Digital therapeutics (DTx) are the companies that deliver a clinical treatment through software itself, at the moment a patient needs it, rather than through a device, a clinician's visit, or a wellness habit. It is also written as prescription digital therapeutics (PDT) or software as a medical device (SaMD); both describe the same shift of a treatment protocol away from a pill, a procedure, or an in-person session and into an app, an algorithm, or a connected sensor's decision logic.
The 20 companies here fall into five segments. Prescription digital therapeutics such as Click Therapeutics, Big Health, HelloBetter and Swing Therapeutics deliver FDA- or DiGA-cleared software treatments that a physician prescribes like a drug. Behavioral health and neurocognitive therapeutics such as Mahana Therapeutics, ieso, Constant Therapy Health and Emocog treat IBS, depression, anxiety and cognitive decline through app-delivered clinical protocols. Cardiometabolic dose-decision software such as Glooko, Glytec and Welldoc turns glucose and vitals data into FDA-cleared dosing recommendations rather than passive tracking. Digital rehabilitation and pediatric therapeutics such as AppliedVR, MedRhythms, Mightier, nyra health and S-Alpha Therapeutics deliver sensor- or game-based rehabilitation and pediatric interventions. Multi-condition DTx platforms such as Sidekick Health and Sweetch license one software engine across dozens of chronic conditions to pharma and payer partners.
The distinction that matters most is against hardware-adjacent and service-adjacent infrastructure, which this list excludes. A continuous glucose monitor, an insulin pump or a neuromodulation wearable still asks a physical sensor or actuator to do the clinical work; a digital therapeutic does not. It either holds the treatment protocol in software the patient interacts with directly, or it delivers an FDA- or DiGA-cleared dosing decision from data, which is why the treatment mechanism, not the device attached to it, is what separates a therapeutic from a monitor.
The table substantiates the economic consequence. Eighteen of 20 companies bill primarily on recurring subscription revenue rather than one-time hardware or procedure fees, which ties revenue to sustained clinical engagement and payer or pharma reimbursement rather than a single purchase. The United States anchors the sector with 12 of 20 companies, but reimbursement pathways built elsewhere, Germany's DiGA formulary and South Korea's MFDS approval track among them, are what let the remaining eight compete globally rather than only regionally.
Excluded from this list: continuous glucose monitors, insulin pumps, neuromodulation wearables and other hardware devices with no software treatment core; telehealth and virtual-clinician services where a person, not an algorithm, delivers the intervention; real-world-evidence and pharma-enablement platforms that supply data infrastructure rather than treat patients directly; diagnostic- or screening-only tools; and companies now operating as subsidiaries of a public or larger private parent.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICS 511210 Software Publishers 621999 All Other Miscellaneous Ambulatory Health Care Services 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing SIC 7372 Prepackaged Software 8049 Offices of Health Practitioners, NEC 3841 Surgical & Medical Instruments & Apparatus Internal taxonomy HLACANAB Prescription Digital Therapeutics (PDT) HLACANAI Behavioral Health & Neurocognitive Therapeutics (Digital) HLAHAHAJ Diabetes Digital Therapeutics & Dose Decision Support HLACANAJ Digital Rehabilitation & Physical Therapy Therapeutics HLACANAL Pediatrics & Adolescent Therapeutics (Digital)Industry codes are provided for cross-referencing against public filings and procurement records. akta.pro's internal classification for this sector is independent of these codes, so a company may carry an internal segment without a matching NAICS or SIC registration.